Meet 2014's Blockbuster Drugs

Meet 2014's Blockbuster Drugs

These five medicines are predicted to be big moneymakers:

Roche’s (RHHBY) experimental leukemia drug beat the company’s top seller, Rituxan, in a trial that may position it as the older treatment’s heir. Annual revenue is forecast to reach $1.4 billion in 2018, based on a Bloomberg survey of six analysts.

Sanofi (SNY) gained access to this antibody-based therapy for multiple sclerosis through its purchase of Genzyme in 2011. The market for MS drugs is forecast to grow from $13.8 billion to $19.6 billion by 2022, according to Credit Suisse (CS).

Johnson & Johnson (JNJ) and Pharmacyclics’ (PCYC) treatment for two types of blood cancer is poised to hit the market earlier than anticipated, after the U.S. Food and Drug Administration designated it a breakthrough therapy. Considered one of the most promising late-stage cancer drugs in the pipeline, ibrutinib has the potential to earn $5 billion a year.

GlaxoSmithKline (GSK) and Theravance (THRX) are collaborating on this treatment for emphysema and chronic bronchitis, which may get final FDA approval as early as December. Anoro is expected to generate $1.2 billion in sales in 2018, according to Bloomberg consensus estimates.

The race is on for an all-oral combination therapy to treat hepatitis C, a disease that attacks the liver, and Gilead Sciences’ (GILD) once-daily pill is in the lead. Analysts expect sofosbuvir to generate $6 billion in sales a year.

Too Cool for Crisis Management

Companies Mentioned

    (Roche Holding AG)
    • $36.65 USD
    • 0.29
    • 0.8%
  • SNY
    • $53.53 USD
    • 0.90
    • 1.68%
Market data is delayed at least 15 minutes.
blog comments powered by Disqus